中国扩张型心肌病诊断和治疗指南:创新与转化

廖玉华

doi:10.13201/j.issn.1001-1439.2018.05.002

中国扩张型心肌病诊断和治疗指南:创新与转化

廖玉华^,

- 华中科技大学同济医学院附属协和医院心内科心血管病研究所生物靶向治疗教育部重点实验室(武汉, 430022)
基金项目:
国家十二五支撑计划项目 (No:2011BAI11B23)

详细信息

通讯作者: 廖玉华,E-mail:liaoyh27@163.com

中图分类号: R542.2

收稿日期: 2018-04-26

Chinese guidelines for diagnosis and treatment of dilated cardiomayopathy:innovation and transformation

LIAO Yuhua^,

- Department of Cardiology, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China

More Information

Corresponding author: LIAO Yuhua, E-mail: liaoyh27@163.com

Received Date: 26 April 2018

摘要

摘要: 《中国扩张型心肌病诊断和治疗指南》依据创新与转化的研究成果, 提出扩张型心肌病 (DCM) 的病因诊断, 临床研究证实抗心肌抗体可以预测DCM猝死和死亡。该指南提出针对DCM病因的免疫学治疗, 临床试验证实通过药物阻止抗体、免疫吸附抗体和免疫调节治疗可以改善DCM患者心功能和降低病死率。
- 扩张型心肌病 /
- 抗心肌抗体 /
- 免疫学治疗
Abstract: According to the innovative and transformative results in Chinese clinical trials, the"2018 Chinese guidelines for diagnosis and treatment of dilated cardiomyopathy (DCM) "proposes the etiological diagnosis of DCM.The clinical studies have confirmed that anti-heart autoantibodies can predict the sudden death and mortality of DCM.Therefore, the guidelines advance a series of noval immunological therapies against the etiological diagnosis of DCM.Those therapies, including blocking antibody by drugs, immuno-absorption antibody and immuno-regulation therapy, are effective in improving cardiac function and decreasing mortality in patients with DCM.
- dilated cardiomyopathy /
- anti-heart autoantibodies /
- immunological therapy

HTML全文

参考文献(10)

[1]	中华医学会心血管病学分会,中国心肌炎心肌病协作组.中国扩张型心肌病诊断和治疗指南[J].临床心血管病杂志,2018,34(5):421-434.doi:10.13201/j.issn.1001-1439.2018.05.001.
[2]	Schultheiss HP,Bolte HD.Immunological analysis of auto-antibodies against the adenine nucleotide translocator in dilated cardiomyopathy[J].J Mol Cell Cardiol,1985,17:603-617.
[3]	Xiao H,Wang M,Du Y,et al.Arrhythmogenic autoantibodies against calcium channel lead to sudden death in idiopathic dilated cardiomyopathy[J].Eur J Heart Fail,2011,13(3):264-270.
[4]	Yu H,Pei J,Liu X,et al. Calcium channel autoantibodies predicted sudden cardiac death and all-cause mortality in patients with ischemic and nonischemic chronic heart failure[J].Dis Markers,2014,2014:796075.doi:10.1155/2014/796075.
[5]	Pei J,Li N,Chen J,et al.The predictive values of beta1-adrenergic and M2 muscarinic receptor autoantibodies for sudden cardiac death in patients with chronic heart failure[J].Eur J Heart Fail,2012,14(8):887-894.
[6]	Nagatomo Y,Yoshikawa T,Okamoto H,et al.Presence of autoantibody directed against b1-adrenergic receptors is associated with amelioration of cardiac function in response to carvedilol:Japanese Chronic Heart Failure (J-CHF) Study[J].J Cardiac Fail,2015,21(3):198-207.
[7]	Waagstein F,Bristow MR,Swedberg K,et al.Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy.Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group[J].Lancet,1993,342:1441- 1446.
[8]	Figulla HR,Gietzen F,Zeymer U,et al.Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy.results of the diltiazem in dilated cardiomyopathy trial[J].Circulation,1996,94:346-352.
[9]	Liao YH.Interventional study of diltiazem in dilated cardiomyopathy:a report of multiple centre clinical trial in China.Chinese cooperative group of diltiazem intervention trial in dilated cardiomyopathy[J].International Journal of Cardiology,1998,64:25-30.
[10]	魏晶晶,袁璟,汪朝晖,等.β受体阻滞剂/地尔硫卓治疗扩张型心肌病患者死亡率的meta分析[J].临床心血管病杂志,2017,33(2):128-132.